What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Jean-Charles Soria mainly investigates Internal medicine, Lung cancer, Cancer research, Oncology and Cancer.
His Internal medicine study combines topics in areas such as Gastroenterology and Surgery.
His Lung cancer research is multidisciplinary, incorporating perspectives in Bevacizumab, Hazard ratio, Response Evaluation Criteria in Solid Tumors and Adenocarcinoma.
His research integrates issues of Carcinogenesis, Immunology, Crizotinib, Breast cancer and ROS1 in his study of Cancer research.
His work carried out in the field of Oncology brings together such families of science as Biomarker, Clinical endpoint, Cisplatin and Epidermal growth factor receptor.
He interconnects Angiogenesis, Toxicity data, Signal transduction and Bioinformatics in the investigation of issues within Cancer.
His most cited work include:
- A genomics-based classification of human lung tumors (354 citations)
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab (320 citations)
- Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab (320 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Cancer, Cancer research and Lung cancer.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery.
His work in Oncology addresses issues such as Pathology, which are connected to fields such as Circulating tumor cell.
His research ties Bioinformatics and Cancer together.
He has researched Cancer research in several fields, including Carcinogenesis, KRAS, Immunology and non-small cell lung cancer.
His Lung cancer course of study focuses on Cisplatin and ERCC1.
He most often published in these fields:
- Internal medicine (58.28%)
- Oncology (45.24%)
- Cancer (33.12%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (58.28%)
- Oncology (45.24%)
- Cancer (33.12%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Oncology, Cancer, Cancer research and Lung cancer.
His work in Internal medicine tackles topics such as Gastroenterology which are related to areas like Refractory and Cohort.
His studies deal with areas such as Precision medicine and Cisplatin as well as Oncology.
His research investigates the connection with Cancer and areas like MEDLINE which intersect with concerns in Metastatic breast.
His studies in Cancer research integrate themes in fields like Tyrosine kinase, Tyrosine-kinase inhibitor, Antibody, Drug resistance and Immunotherapy.
His Lung cancer research is multidisciplinary, incorporating elements of Pneumonia, KRAS, Carcinoma, Hazard ratio and Adenocarcinoma.
Between 2017 and 2021, his most popular works were:
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study (297 citations)
- A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study (297 citations)
- Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy (285 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Jean-Charles Soria mostly deals with Internal medicine, Lung cancer, Oncology, Gastroenterology and Cancer research.
His study involves Carcinoma, Cohort, Clinical endpoint, Retrospective cohort study and Cancer, a branch of Internal medicine.
His research in Lung cancer intersects with topics in Response Evaluation Criteria in Solid Tumors, Pneumonia and Hazard ratio.
His Oncology research integrates issues from Head and neck squamous-cell carcinoma, Pharmacokinetics, Pharmacodynamics and Metastatic breast cancer.
While the research belongs to areas of Gastroenterology, Jean-Charles Soria spends his time largely on the problem of Adverse effect, intersecting his research to questions surrounding Refractory, Refractory B-Cell Non-Hodgkin Lymphoma, Lymphoma, Atezolizumab and Immunohistochemistry.
Jean-Charles Soria combines subjects such as AKT1, Metastasis, Drug resistance and Immunotherapy with his study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
